MARGUERITE ADAMS: Open Payments
NPI 1164139796 · TOWSON, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,941 in 166 payments from 27 companies in 2025. Trend: 2023 $3,369 · 2024 $1,548 · 2025 $3,941
Food & beverage: $3,941
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 17 | $567 |
| ABBVIE INC. | 32 | $528 |
| Madrigal Pharmaceuticals | 9 | $354 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $281 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 13 | $265 |
| Regeneron Healthcare Solutions, Inc. | 15 | $226 |
| Phathom Pharmaceuticals, Inc. | 9 | $205 |
| PFIZER INC. | 11 | $200 |
| GENZYME CORPORATION | 6 | $173 |
| Ipsen Biopharmaceuticals, Inc | 5 | $151 |
Products named: TREMFYA, DUPIXENT, REZDIFFRA, XIFAXAN, CREON, VOQUEZNA, ENTYVIO, IQIRVO.
Industry payments across MD — which companies pay providers there.
